Drugs /

mk2206

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Clinical Trials

View Clinical Trials for mk2206

Mk2206 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating mk2206, 2 are phase 2 (1 open).

PIK3CA Mutation, AKT1 Mutation, and AKT2 Mutation are the most frequent biomarker inclusion criteria for mk2206 clinical trials.

Breast carcinoma, non-small cell lung carcinoma, and small cell lung carcinoma are the most common diseases being investigated in mk2206 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mk2206
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Mk2206
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mk2206 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mk-2206, akt inhibitor mk2206, mk 2206
Drug Categories [2]:
AKT inhibitors, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
AKT1, AKT2, AKT3
NCIT ID [1]:
C90581

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.